Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)

Due: Jun 28, 2024

$3,500,000

Description

The purpose of this notice of funding opportunity (NOFO) is to support the evaluation of early-stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical algorithms in TB endemic countries. Evaluation studies should:

1) perform proof-of principle studies of novel diagnostic tests and strategies for TB, including among people living with HIV (PLWH) and 2) provide feedback to diagnostic developers and policy makers on...

Award Ceiling$3,500,000

Eligible Applicants- State governments- County governments- City or township governments- Special district governments- Independent school districts- Public and State controlled institutions of higher education- Native American tribal governments (Federally recognized)- Public housing authorities/Indian housing authorities- Native American tribal organizations (other than Federally recognized tribal governments)- Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education- Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education- Private institutions of higher education- For-profit organizations other than small businesses- Small businesses- Others

Additional Eligibility Information

Other Eligible Applicants include the following:Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Cont...

Funding TypeGrantCategories of Funding Activity- HealthOpportunity TypeDiscretionary

Grantor Contact InformationSee Section VII. Agency Contacts within the full opportunity announcement for all other inquires.Grantor Emailgrantsinfo@nih.govOther Grantor InformationNIH Grants Information grantsinfo@nih.gov

Additional Informationhttps://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-010.htmlSupporting Linkhttp://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-010.html

Start finding grants with Atom for

$0 today

$30 Billed monthly after 7-day trial. Cancel anytime.

Personalized grant emails delivered weekly, right to your inbox.

AI powered search engine with both keyword and semantic search capabilities.

Grant filters to find the perfect funding opportunities.

Similar Grants

Eligibility

Profile

Finance

Other

Similar Grants

Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)

Start finding grants with Atom for

$0 today

$30 Billed monthly after 7-day trial. Cancel anytime.

Personalized grant emails delivered weekly, right to your inbox.

AI powered search engine with both keyword and semantic search capabilities.

Grant filters to find the perfect funding opportunities.

Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)

Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)

Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)

Start finding grants with Atom for

$0 today

$30 Billed monthly after 7-day trial. Cancel anytime.

Personalized grant emails delivered weekly, right to your inbox.

AI powered search engine with both keyword and semantic search capabilities.

Grant filters to find the perfect funding opportunities.

Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)

Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)